symbol
stringclasses 26
values | publishedDate
timestamp[ns] | title
stringlengths 3
421
| image
stringlengths 38
271
⌀ | site
stringclasses 104
values | text
stringlengths 0
69k
| url
stringlengths 19
468
|
|---|---|---|---|---|---|---|
TSLA
| 2021-06-01T05:05:54 |
China Tesla rival Nio sees deliveries fall in May as chip shortage bites
|
cnbc.com
|
Nio delivered 6,711 vehicles in May, a 95.3% year-on-year. However, that was a 5% decrease from April.
|
https://www.cnbc.com/2021/06/01/chinas-xpeng-motors-ev-deliveries-accelerate-and-nio-declines-in-may-.html
|
|
AAPL
| 2021-06-01T05:19:44 |
Apple To Continue Investing In Retail Stores Despite Increasing Online-Sale Shift
|
benzinga.com
|
Apple Inc (NASDAQ: AAPL) will continue to scale up its global retail presence as physical stores help create a connection with consumers, a company executive told Germany's Funke Mediengruppe (via Bloomberg). What Happened: Despite a growing preference to buy online during the COVID-19 pandemic, the iPhone maker sees merit in adding more physical stores, Deirdre O'Brien, senior vice president of retail and people at Apple, told Funke.
|
https://www.benzinga.com/news/21/06/21360679/apple-to-continue-investing-in-retail-stores-despite-increasing-online-sale-shift
|
|
GOOGL
| 2021-06-01T05:51:41 |
Alphabet Stock: Cloud Business Is Not Priced In
|
seekingalpha.com
|
Alphabet Q1 2021 results show that it's back on its front foot.
|
https://seekingalpha.com/article/4432337-alphabet-fast-growing-cloud-business-and-cheap-stock
|
|
MSFT
| 2021-06-01T06:15:00 |
If I Could Own Only One Stock, This Would Be It
|
fool.com
|
For those new to investing, this would also be my pick as your first core holding.
|
https://www.fool.com/investing/2021/06/01/if-i-could-only-own-one-stock-this-would-be-it/
|
|
AMZN
| 2021-06-01T06:24:00 |
Why Amazon's Purchase of MGM Will Do Little for Amazon Stock
|
fool.com
|
What benefits Prime members does not necessarily help investors.
|
https://www.fool.com/investing/2021/06/01/why-amazons-purchase-of-mgm-will-do-little-for-ama/
|
|
AMZN
| 2021-06-01T06:45:00 |
How Target Won the Pandemic
|
fool.com
|
Target has thrived during the pandemic, and it may be set up to grow even more long term.
|
https://www.fool.com/investing/2021/06/01/how-target-won-the-pandemic/
|
|
AMZN
| 2021-06-01T07:00:00 |
Amazon Opens Disaster Relief Hub in Atlanta for Faster Response to Natural Disasters
|
businesswire.com
|
ATLANTA--(BUSINESS WIRE)--Amazon (NASDAQ: AMZN) announced today the opening of its first Disaster Relief Hub, a facility near Atlanta storing emergency supplies to quickly help our front-line community partners respond to natural disasters across the southeastern U.S., the Caribbean, and Central America. The hub will stock over a half a million Amazon-donated relief supplies in 10,000 cubic feet of fulfillment center space—enough to fill an Amazon Air 767 cargo plane and immediately provide critical supplies when a disaster strikes. Atlanta is located 310 miles from the Gulf Coast, 734 miles from the Bahamas, and within 1,535 miles of Puerto Rico and other Caribbean islands—areas that experience the most active hurricane season. Atlanta’s close proximity to the Gulf Coast, the Caribbean region, and Central America will help Amazon’s community partners swiftly respond to hurricanes, floods, and other natural disasters. “Our disaster relief and response team is partnering with global humanitarian relief organizations to leverage Amazon’s scale to help improve response time to large-scale natural disasters around the world,” said Alicia Boler Davis, vice president of Global Customer Fulfillment at Amazon. “Our expertise in logistics and operations allows us to be nimble, fast, and effective. We’ve created the Disaster Relief Hub in metro Atlanta to provide rapid relief when it’s needed most by donating and delivering hundreds of thousands of emergency aid supplies, including shelter materials like tents and tarps, hygiene items, and medical equipment.” When a natural disaster hits, emergency teams quickly assess what supplies they have, procure items they need, and then consolidate, pack, and ship supplies into disaster zones. The process can take multiple days. To quicken that crucial timeframe, Amazon analyzed its data across four years of disaster support and formed a pre-positioning strategy. The strategy is tailored to the most common relief supplies needed by our community partners to do their lifesaving work. Those supplies include tarps, tents, water containers and filters, medical equipment, clothing items, and kitchen supplies. Once those critical relief items are on the first flight out, Amazon works with community partners to identify other needed supplies from Amazon’s vast selection of products and fills additional, unique critical needs. “I am thankful to Amazon for using their resources and humanitarian aid network to respond to disasters in our state, nation, and world through the new Disaster Relief Hub,” said Georgia Governor Brian Kemp. “With Amazon recently announcing the opening of a fulfillment center in South Georgia, to now announcing the opening of the Disaster Relief Hub in Atlanta, it is clear Amazon sees the many benefits of establishing itself in the Peach State. I am grateful for their commitment to bettering the lives of countless Georgians.” The Disaster Relief Hub will initially support six global humanitarian aid organizations: the American Red Cross, Direct Relief, the International Federation of Red Cross and Red Crescent Societies, International Medical Corps, Save the Children, and World Central Kitchen. “When a large natural disaster happens, companies like Amazon play an important role in how the American Red Cross responds to help communities and families in immediate need,” said Trevor Riggen, senior vice president of Disaster Cycle Services at the American Red Cross. “Amazon’s commitment to disaster relief and preparedness aligns with our mission to help disaster survivors. In order to fulfill this mission, we must have stocked warehouses, trained volunteers, and state-of-the-art systems in place. Amazon’s donation of critical relief supplies and advance pre-positioning efforts allows the Red Cross to stand ready to help at a moment’s notice. We’re honored to count Amazon as one of our most valued partners and are grateful for their continued support to fulfill our mission.” Since 2017, Amazon has donated more than $29 million in cash and in-kind products in response to 59 natural disasters around the world. Amazon’s 2021 disaster relief and response efforts so far include donating and sending critical medical equipment worth over $5 million to support hospitals and other COVID-19 care facilities across India. Additionally, Amazon donated and delivered over 1 million bottles of water and thousands of items such as tents, flashlights, and search and rescue equipment to communities impacted by severe storms earlier this year in Texas, Mississippi, Tennessee, and Alabama. In 2020, Amazon donated more than 1 million emergency aid items to communities in the U.S. and abroad hit by hurricanes and wildfires, including water, generators, air filters, food, KN95 masks, and cleaning supplies. The efforts helped community partners providing disaster relief to people affected by wildfires in California, Oregon, and Washington state; Hurricane Laura along the Gulf Coast; earthquakes in Puerto Rico; and Hurricanes Eta and Iota in Central America and the Caribbean. Amazon's disaster relief and response efforts leverage Amazon's vast operational excellence, innovative technologies, and global logistics network to provide fast and effective support to worldwide operations fighting large-scale natural disasters. Amazon has filled cargo jets and shipped truckloads of Amazon-donated items for communities ravaged by hurricanes, sent solar-powered lights to people living without power after tsunamis, enabled customers to easily donate products and cash on Amazon.com, and helped organizations including governments and nonprofits expedite response efforts at scale through our Amazon Web Services (AWS) cloud services. About Amazon Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
|
https://www.businesswire.com/news/home/20210601005295/en/Amazon-Opens-Disaster-Relief-Hub-in-Atlanta-for-Faster-Response-to-Natural-Disasters
|
|
MRNA
| 2021-06-01T07:30:00 |
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
|
businesswire.com
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. “We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.” Moderna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks with a request for a Priority Review. Once the rolling BLA submission is complete, FDA will notify the Company when it is formally accepted for review. The Moderna COVID-19 Vaccine is currently available in the U.S. under an Emergency Use Authorization (EUA), which was granted on December 18, 2020. As of today, according to the U.S. Centers for Disease Control and Prevention (CDC), more than 124 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S. About the Moderna COVID-19 Vaccine The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the National Institutes of Health (NIH) on February 24, 2020, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on March 16, 2020, 63 days from sequence selection to Phase 1 study dosing. On May 12, 2020, the U.S. FDA granted the Moderna COVID-19 Vaccine Fast Track designation. On May 29, 2020, the first participants in each age cohort were dosed in the Phase 2 study of the vaccine. On July 8, 2020, the Phase 2 study completed enrollment. Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29, 2020 in The New England Journal of Medicine. On November 30, 2020, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. On November 30, 2020, the Company also announced that it filed for Emergency Use Authorization with the U.S. FDA and a Conditional Marketing Authorization (CMA) application with the European Medicines Agency. On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has also received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, the Philippines, Thailand, Brunei, Paraguay, Japan, South Korea, and an Emergency Use Listing (EUL) from the World Health Organization (WHO). Preclinical data on the Company’s variant-specific booster vaccine candidates have been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication. These variant-specific vaccine candidates include mRNA-1273.351, which is more specifically targeted against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and a multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 (Moderna’s authorized vaccine against ancestral strains) and mRNA-1273.351 in a single vaccine. The Company’s Phase 2 study to evaluate three approaches to boosting is ongoing. The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) is supporting the continued research and development of the Company’s COVID-19 vaccine development efforts with federal funding under contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to purchase supply of mRNA-1273 under U.S. Department of Defense contract no. W911QY-20-C-0100. AUTHORIZED USE Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. IMPORTANT SAFETY INFORMATION Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine. Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html). Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID-19 Vaccine. The Moderna COVID-19 Vaccine may not protect all vaccine recipients. Adverse reactions reported in a clinical trial following administration of the Moderna COVID-19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site. Severe allergic reactions, including anaphylaxis, have been reported following administration of the Moderna COVID-19 Vaccine during mass vaccination outside of clinical trials. Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion. There are no data available on the interchangeability of the Moderna COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine. Vaccination providers must complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words “Moderna COVID-19 Vaccine EUA” in the description section of the report. Click for Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information for more information. About Moderna In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic. Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company’s application for a Biologics License Application for the Moderna COVID-19 Vaccine, the timing for the application and next steps with the U.S. FDA. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; the Moderna COVID-19 Vaccine may prove less effective against variants of the SARS-CoV-2 virus, or the Company may be unsuccessful in developing future versions of its vaccine against these variants; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or additional emergency use authorization applications may be filed in various jurisdictions and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
|
https://www.businesswire.com/news/home/20210601005270/en/Moderna-Announces-Initiation-of-Rolling-Submission-of-Biologics-License-Application-BLA-with-U.S.-FDA-for-the-Moderna-COVID-19-Vaccine
|
|
MRNA
| 2021-06-01T07:30:00 |
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
|
businesswire.com
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces initiation of rolling submission of Biologics License Application (BLA) with the U.S. FDA for the Moderna COVID-19 vaccine.
|
https://www.businesswire.com/news/home/20210601005270/en/Moderna-Announces-Initiation-of-Rolling-Submission-of-Biologics-License-Application-BLA-with-U.S.-FDA-for-the-Moderna-COVID-19-Vaccine/
|
|
MSFT
| 2021-06-01T07:33:20 |
C3.ai Could Become Like Microsoft in the 1990s
|
investorplace.com
|
Even though AI stock has a high price-sales ratio, the shares could surge tremendously over the next three or four years. The post C3.ai Could Become Like Microsoft in the 1990s appeared first on InvestorPlace.
|
https://investorplace.com/2021/06/c3-ai-stock-could-become-like-microsoft-in-the-1990s/
|
|
AMZN
| 2021-05-31T07:31:09 |
4 Stocks to Watch as Demand for Video Streaming Heats Up
|
zacks.com
|
Watch out for names like Apple (AAPL), Netflix (NFLX), Amazon (AMZN) and Disney (DIS) as demand for video streaming services continues to rise.
|
https://www.zacks.com/stock/news/1633271/4-stocks-to-watch-as-demand-for-video-streaming-heats-up
|
|
NVDA
| 2021-05-31T08:00:00 |
Forget the Stock Split, 3 Reasons NVIDIA Could Continue to Climb in 2021
|
fool.com
|
2021 got off to a great start, and sales momentum is set to continue through the year.
|
https://www.fool.com/investing/2021/05/31/forget-stock-split-reasons-nvidia-could-climb/
|
|
AMZN
| 2021-05-31T08:30:00 |
2 Stocks for Beginning Investors
|
fool.com
|
These companies are strong choices to hold onto for a long time.
|
https://www.fool.com/investing/2021/05/31/2-stocks-for-beginning-investors/
|
|
AMZN
| 2021-05-31T09:00:00 |
How MGM Helps Transform Amazon Prime Video
|
fool.com
|
Amazon wants Prime Video to be more than just an add-on for Prime members.
|
https://www.fool.com/investing/2021/05/31/how-mgm-helps-transform-amazon-prime-video/
|
|
COST
| 2021-05-31T09:08:00 |
Costco Earnings: Another Impressive Quarter
|
fool.com
|
The leading wholesale club operator reported extraordinary earnings growth in the third quarter of its 2021 fiscal year.
|
https://www.fool.com/investing/2021/05/31/costco-earnings-another-impressive-quarter/
|
|
AMGN
| 2021-05-31T09:46:18 |
Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer
|
zacks.com
|
FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.
|
https://www.zacks.com/stock/news/1633578/amgens-amgn-kras-inhibitor-gets-fda-nod-for-lung-cancer
|
|
NVDA
| 2021-05-31T09:46:18 |
Nvidia (NVDA) Boasts Earnings & Price Momentum: Should You Buy?
|
zacks.com
|
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
|
https://www.zacks.com/stock/news/1633792/nvidia-nvda-boasts-earnings-price-momentum-should-you-buy
|
|
NFLX
| 2021-05-31T10:31:00 |
HBO Max Is Trying to Use Disney and Netflix's Playbook
|
fool.com
|
It's copying the competition's pricing strategies for its international expansion.
|
https://www.fool.com/investing/2021/05/31/hbo-max-trying-to-use-disney-and-netflix-playbook/
|
|
TSLA
| 2021-05-31T11:20:14 |
Nio's William Li: EV Maker Has Built Premium Reputation With ASPs Outstripping Audi, BMW And Tesla
|
benzinga.com
|
China's NIO Inc. (NYSE: NIO) has positioned itself as a manufacturer of premium-end vehicles, carving a niche for itself in this segment. What Happened: Nio's founder, chairman and CEO William Li, reiterated the company's focus on the high-end of the market and provided some statistics to corroborate the claim, CnEVPost reported, citing a speech by Li at the 4th China Young Entrepreneurs Summit on Sunday.
|
https://www.benzinga.com/media/21/05/21353295/nios-william-li-ev-maker-has-built-premium-reputation-with-asps-outstripping-audi-bmw-and-tesla
|
|
TXN
| 2021-05-31T12:02:05 |
Is Texas Instruments (TXN) Outperforming Other Computer and Technology Stocks This Year?
|
zacks.com
|
Is (TXN) Outperforming Other Computer and Technology Stocks This Year?
|
https://www.zacks.com/stock/news/1634277/is-texas-instruments-txn-outperforming-other-computer-and-technology-stocks-this-year
|
|
NFLX
| 2021-05-31T12:47:22 |
GTN or NFLX: Which Is the Better Value Stock Right Now?
|
zacks.com
|
GTN vs. NFLX: Which Stock Is the Better Value Option?
|
https://www.zacks.com/stock/news/1634296/gtn-or-nflx-which-is-the-better-value-stock-right-now
|
|
TSLA
| 2021-05-31T12:47:23 |
GM vs. TSLA: Which Stock Is the Better Value Option?
|
zacks.com
|
GM vs. TSLA: Which Stock Is the Better Value Option?
|
https://www.zacks.com/stock/news/1634293/gm-vs-tsla-which-stock-is-the-better-value-option
|
|
SBUX
| 2021-05-31T14:05:59 |
Is June a good month for investing in Starbucks shares?
|
invezz.com
|
Starbucks Corporation (NASDAQ: SBUX) shares have been moving in an uptrend last several months, and according to technical analysis, there is no risk of the bear market for now. Starbucks has a very good position in the market, but the current share price does not provide an attractive entry point for long-term investors.
|
https://invezz.com/news/2021/05/31/is-june-a-good-month-for-investing-in-starbucks-shares/
|
|
AAPL
| 2021-05-31T15:48:00 |
Apple, Facebook, Twitter price analysis roundup
|
invezz.com
|
Wall Street's three main indexes advanced last week after better than expected data released from the U.S., which confirmed that the economy continues to recover from the pandemic. The country has reported a drop in jobless claims and a 1% rise in core durable goods serving to highlight the improvements seen in April and May.
|
https://invezz.com/news/2021/05/31/apple-facebook-twitter-price-analysis-roundup/
|
|
AAPL
| 2021-05-31T16:30:01 |
New Street Research says Apple is a ‘sell': here is what they got right
|
invezz.com
|
Shares of Apple Inc. (NASDAQ:AAPL) fell more than 2% on Friday after New Street Research analyst Pierre Ferragu downgraded the stock from a neutral rating to a sell rating. Ferragu also gave AAPL a new price target of $90 which implies a downside potential of about 28% based on Friday's closing price.
|
https://invezz.com/news/2021/05/31/new-street-research-says-apple-is-a-sell-here-is-what-they-got-right/
|
|
TSLA
| 2021-05-31T20:24:00 |
Tesla's vehicle price increases due to supply chain pressure, Musk says
|
reuters.com
|
The price of Tesla vehicles is increasing due to supply chain pressures across the auto industry, particularly for raw materials, Elon Musk said on Monday in response to a tweet https://bit.ly/3vFEtQL.
|
https://www.reuters.com/business/autos-transportation/teslas-vehicle-price-increases-due-supply-chain-pressure-musk-says-2021-06-01/
|
|
TSLA
| 2021-05-31T21:58:53 |
Elon Musk says Tesla prices are increasing because of supply chain disruptions across the auto industry
|
businessinsider.com
|
Prices on some Tesla models are increasing due to global supply chain disruptions in the auto industry, particularly with raw materials, Elon Musk said on Twitter Monday. Musk's explanation came in response to a Twitter user who said they didn't like the "direction" the company was going in by "raising prices of vehicles but removing features like lumbar for the Model Y."
|
https://www.businessinsider.com/elon-musk-tesla-price-increases-result-of-supply-chain-disruptions-2021-5
|
|
AMD
| 2021-05-31T23:00:00 |
AMD Unveils RDNA 2-Based Mobile Graphics, New AMD Advantage Laptops, Broadly Compatible Upscaling Technology and More at Computex 2021
|
globenewswire.com
|
– AMD Radeon RX 6000M Series Mobile Graphics provide a generational performance leap of up to 1.5X, powering the next generation of premium gaming laptops from ASUS, HP, Lenovo, MSI and other leading OEMs –
|
https://www.globenewswire.com/news-release/2021/06/01/2239109/0/en/AMD-Unveils-RDNA-2-Based-Mobile-Graphics-New-AMD-Advantage-Laptops-Broadly-Compatible-Upscaling-Technology-and-More-at-Computex-2021.html
|
|
AAPL
| 2021-05-30T09:32:12 |
Week 22 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge
|
seekingalpha.com
|
Two new sample breakout stocks for Week 22 with better than 10% short-term upside potential. This past week the portfolio gained +4.4% led by gains in CDEV +15.6% and 3 out of 4 picks gaining more than +6.2% in less than 5 days.
|
https://seekingalpha.com/article/4432114-week-22-mda-breakout-stocks-june-2021-short-term-picks-to-give-you-an-edge
|
|
ADBE
| 2021-05-30T11:02:16 |
Third Point Exits Alibaba, Fidelity
|
gurufocus.com
|
Daniel Loeb (Trades, Portfolio)'s Third Point, LLC sold shares of the following stocks during the first quarter of 2021, which ended on March 31.
|
https://www.gurufocus.com/news/1441744/third-point-exits-alibaba-fidelity
|
|
NVDA
| 2021-05-30T11:08:00 |
NVIDIA and Corsair Gaming Are the Best Bets on This Terrific Opportunity
|
fool.com
|
These two companies are in a solid position to take advantage of the fast-growing esports industry.
|
https://www.fool.com/investing/2021/05/30/nvidia-and-corsair-best-bets-on-this-opportunity/
|
|
AVGO
| 2021-05-30T15:00:00 |
Zoom, Lululemon, Canopy Growth, and Other Stocks to Watch This Week
|
barrons.com
|
Markets are closed for Memorial Day. Then, Zoom, Broadcom, Lululemon, and Canopy Growth report earnings.
|
https://www.barrons.com/articles/zoom-lululemon-canopy-growth-and-other-stocks-for-investors-to-watch-this-week-51622401200
|
|
COST
| 2021-05-30T15:05:00 |
3 Top Stocks to Recession-Proof Your Portfolio
|
fool.com
|
Some investments have all-weather appeal. You're going to want to own these three stocks when it rains.
|
https://www.fool.com/investing/2021/05/30/3-top-stocks-to-recession-proof-your-portfolio/
|
|
AMZN
| 2021-05-30T22:36:51 |
Arlo: A Top Speculative Buy
|
seekingalpha.com
|
Arlo: A Top Speculative Buy
|
https://seekingalpha.com/article/4432155-arlo-a-top-speculative-buy
|
|
MSFT
| 2021-05-31T03:01:16 |
‘Silicon Six' tech giants accused of inflating tax payments by almost $100bn
|
theguardian.com
|
Study claims firms paid $96bn less in tax between 2011 and 2020 than the notional figures cited in their annual reports
|
https://www.theguardian.com/business/2021/may/31/silicon-six-tech-giants-accused-of-inflating-tax-payments-by-almost-100bn
|
|
META
| 2021-05-31T05:51:00 |
5 Stocks That Can Help You Achieve Financial Freedom
|
fool.com
|
Investing in great businesses over the long run is an unrivaled path to financial independence.
|
https://www.fool.com/investing/2021/05/31/5-stocks-can-help-you-achieve-financial-freedom/
|
|
MRNA
| 2021-05-31T06:00:00 |
Here's How Moderna Plans to Beat the Biggest Threat to Its Vaccine
|
fool.com
|
Moderna's strengths in technology may give it an edge.
|
https://www.fool.com/investing/2021/05/31/heres-how-moderna-plans-to-beat-the-biggest-threat/
|
|
TSLA
| 2021-05-31T06:00:47 |
Lucid Motors Stock Is A Higher-Risk Version Of Tesla
|
investorplace.com
|
Lucid Motors stock is one of the newest ways to invest in EVs. However, Lucid investors should understand the investment is a long shot.
|
https://investorplace.com/2021/05/lucid-motors-stock-is-a-higher-risk-version-of-tesla/
|
|
NVDA
| 2021-05-31T06:05:00 |
Is the Growth Stock Bull Market About to Make a Comeback?
|
fool.com
|
There are some signs that Wall Street is warming up again to growth stocks.
|
https://www.fool.com/investing/2021/05/31/is-the-growth-stock-bull-market-back/
|
|
AAPL
| 2021-05-31T07:31:09 |
4 Stocks to Watch as Demand for Video Streaming Heats Up
|
zacks.com
|
Watch out for names like Apple (AAPL), Netflix (NFLX), Amazon (AMZN) and Disney (DIS) as demand for video streaming services continues to rise.
|
https://www.zacks.com/stock/news/1633271/4-stocks-to-watch-as-demand-for-video-streaming-heats-up
|
|
AAPL
| 2021-05-29T12:02:19 |
Apple's massive success with CarPlay paves the way for automotive ambitions
|
cnbc.com
|
Automotive manufacturers and their suppliers were excited about building sophisticated apps for car dashboards. Then Apple came in and changed everything.
|
https://www.cnbc.com/2021/05/29/apple-carplay-massive-success-paves-way-for-automotive-entry.html
|
|
COST
| 2021-05-29T22:59:09 |
COST Stock Price: $450 Target From Barclays
|
pulse2.com
|
The shares of Costco Wholesale Corporation (NASDAQ: COST) have received a price target increase from $400 to $450 by Barclays. These are the details.
|
https://pulse2.com/cost-stock-price-450-target-from-barclays/
|
|
TSLA
| 2021-05-30T05:36:00 |
Answer These 5 Questions Before Investing in Bitcoin
|
fool.com
|
Thinking of putting some money into the popular cryptocurrency? Don't make that move until you address these important points.
|
https://www.fool.com/investing/2021/05/30/answer-these-5-questions-before-investing-in-bitco/
|
|
AMZN
| 2021-05-30T05:51:00 |
Prediction: These Will Be the 10 Largest Stocks by 2035
|
fool.com
|
Change is inevitable. The biggest stocks in the world by market cap will undoubtedly look a bit different in 14 years.
|
https://www.fool.com/investing/2021/05/30/prediction-these-will-be-10-largest-stocks-by-2035/
|
|
COST
| 2021-05-30T06:00:00 |
3 Top Investments to Help You Fight Inflation
|
fool.com
|
You don't have to worry about inflation if you prepare your portfolio for its impact in advance.
|
https://www.fool.com/investing/2021/05/30/3-top-investments-to-help-you-fight-inflation/
|
|
AMGN
| 2021-05-30T06:11:00 |
Could Nano-X Be a Millionaire-Maker Stock?
|
fool.com
|
Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible.
|
https://www.fool.com/investing/2021/05/30/could-nano-x-be-a-millionaire-maker-stock/
|
|
TSLA
| 2021-05-30T07:00:00 |
Giant Pension Slashed Intel, Tesla Stakes. It Scooped Up Covid-Vaccine Makers.
|
barrons.com
|
Canadian Pension Plan Investment Board cut more than three-quarters of positions in chip giant Intel and electric-vehicle maker Tesla, and bought Moderna and Pfizer stock in the first quarter.
|
https://www.barrons.com/articles/pension-sold-intel-tesla-stock-bought-vaccine-makers-moderna-pfizer-51622054350
|
|
AMZN
| 2021-05-30T07:47:41 |
The Next Chapter of the Streaming Wars: Media Merger Mania
|
gurufocus.com
|
When the Walt Disney Co. ( DIS , Financial) launch Disney+ in November 2019, it marked a serious escalation of the so-called "Streaming Wars."
|
https://www.gurufocus.com/news/1441427/the-next-chapter-of-the-streaming-wars-media-merger-mania
|
|
AMZN
| 2021-05-30T08:24:00 |
5 Stocks You Can Buy and Hold Forever
|
fool.com
|
The growth catalysts for these stocks are so compelling, you'd want to own them forever.
|
https://www.fool.com/investing/2021/05/30/5-stocks-you-can-buy-and-hold-forever/
|
|
AMD
| 2021-05-30T08:24:06 |
These are Wall Street's top analysts favorite stocks heading into June
|
cnbc.com
|
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Deere & Advanced Micro Devices.
|
https://www.cnbc.com/2021/05/30/wall-street-analysts-say-buy-stocks-deere-advanced-micro-devices.html
|
|
AMZN
| 2021-05-30T08:30:00 |
3 Unstoppable Cloud Stocks to Buy Right Now
|
fool.com
|
These tech stocks are leading in their respective cloud markets -- here's why investors would be wise to pay attention.
|
https://www.fool.com/investing/2021/05/30/3-unstoppable-cloud-stocks-to-buy-right-now/
|
|
PEP
| 2021-05-30T09:00:00 |
Upcoming Ex-Dividend Dates: June 1-14, 2021
|
seekingalpha.com
|
This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.
|
https://seekingalpha.com/article/4432091-upcoming-ex-dividend-dates-june-1-14-2021
|
|
AMGN
| 2021-05-28T17:00:00 |
Amgen To Present At The 2021 Jefferies Healthcare Conference
|
prnewswire.com
|
THOUSAND OAKS, Calif., May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m.
|
https://www.prnewswire.com/news-releases/amgen-to-present-at-the-2021-jefferies-healthcare-conference-301301907.html
|
|
PEP
| 2021-05-28T17:26:28 |
Should I buy PepsiCo shares after UBS raised its price target to $165?
|
invezz.com
|
PepsiCo, Inc. (NASDAQ: PEP) shares are advancing this Friday, and the technical picture implies that the price could reach $150 resistance in the upcoming days. The U.S. stock market also remains supported as the prospect of a $6 trillion budget from U.S. president Biden helped lift investors' mood.
|
https://invezz.com/news/2021/05/28/should-i-buy-pepsico-shares-after-ubs-raised-its-price-target-to-165/
|
|
AMZN
| 2021-05-28T17:28:00 |
Call for Amazon to consider blue-collar director wins 17% support
|
reuters.com
|
A shareholder proposal calling for Amazon.com Inc to consider adding an hourly worker to its board of directors received support from 17% of votes cast, according to a company filing on Friday.
|
https://www.reuters.com/article/us-amazon-investors-workers/call-for-amazon-to-consider-blue-collar-director-wins-17-support-idUSKCN2D92H9
|
|
AAPL
| 2021-05-28T17:38:33 |
4 Top Stock Trades for Tuesday: AAPL, BB, BIG, SNAP
|
investorplace.com
|
Apple, BlackBerry, Big Lots and Snap were our top stock trades for next week. Now let's look at what the charts are telling us after Friday.
|
https://investorplace.com/2021/05/4-top-stock-trades-for-tuesday-aapl-bb-big-snap/
|
|
PEP
| 2021-05-28T18:10:30 |
Home Improvement, Beverage Stocks to Rise: BofA's Suzuki
|
youtube.com
|
May.28 -- Liz Suzuki, Bank of America Securities analyst talks about the stocks she's watching this Memorial Day weekend.
|
https://www.youtube.com/watch?v=RpvRcn8KD68
|
|
NVDA
| 2021-05-28T19:28:01 |
Here's Why NVIDIA Stock Jumped Today
|
fool.com
|
The bulls are taking the reins once again.
|
https://www.fool.com/investing/2021/05/28/heres-why-nvidia-stock-jumped-today/
|
|
TSLA
| 2021-05-28T19:49:58 |
The hot EV trade
|
youtube.com
|
CNBCs Phil LeBeau looks at what's driving the electric vehicle boom. With CNBC's Courtney Reagan and the Fast Money traders, Victoria Fernandez, Delano Saporu and Tim Seymour.
|
https://www.youtube.com/watch?v=6fOf_BlNLfI
|
|
TSLA
| 2021-05-29T07:00:00 |
Huge Pension Cuts AT&T Stake. It Bought Tesla, McDonald's, and One Chinese Stock.
|
barrons.com
|
The manager of Wisconsin's pension more than halved its AT&T stake in the first quarter. It also tripled its holdings of Tesla stock, and bought more McDonald's and NIO shares.
|
https://www.barrons.com/articles/pension-sold-att-stock-it-bought-tesla-mcdonalds-nio-51622039941
|
|
SBUX
| 2021-05-29T07:27:00 |
Better Buy: Starbucks vs. Chipotle
|
fool.com
|
The winner here ultimately comes down to price.
|
https://www.fool.com/investing/2021/05/29/better-buy-starbucks-vs-chipotle/
|
|
AMZN
| 2021-05-29T08:13:00 |
Don't Waste Your Money on Penny Stocks, These 3 Stocks Are Better Buys
|
fool.com
|
Even $100 invested in these three stocks could help you to set up your portfolio for long-term success.
|
https://www.fool.com/investing/2021/05/29/dont-waste-your-money-on-penny-stocks-these-3-stoc/
|
|
META
| 2021-05-29T08:15:00 |
Better Buy: Facebook vs. Pinterest
|
fool.com
|
These two social media companies are competing for ad dollars.
|
https://www.fool.com/investing/2021/05/29/better-buy-facebook-vs-pinterest/
|
|
GOOG
| 2021-05-29T08:30:00 |
3 Stocks to Bankroll Your Retirement
|
fool.com
|
Only the best-grounded and most flexible companies belong in a retirement account that absolutely has to grow.
|
https://www.fool.com/investing/2021/05/29/3-stocks-to-bankroll-your-retirement/
|
|
TSLA
| 2021-05-29T08:30:01 |
How Tesla is quietly expanding its energy storage business
|
cnbc.com
|
In 2015, Elon Musk announced Tesla would get into the energy business, and it has been slowly ramping up deployments of its energy storage products since.
|
https://www.cnbc.com/2021/05/29/elon-musk-and-tesla-are-quietly-expanding-its-energy-storage-business.html
|
|
NVDA
| 2021-05-29T08:45:00 |
Investors Who Worry About Bitcoin Should Remember These 3 Things
|
fool.com
|
Bitcoin is still down about 40% from its recent high, but there are several reasons to believe the future is golden.
|
https://www.fool.com/investing/2021/05/29/investors-who-worry-about-bitcoin-should-remember/
|
|
TSLA
| 2021-05-29T08:46:05 |
TSLA Stock Price: $590 Target By Wells Fargo
|
pulse2.com
|
The shares of Tesla Inc (NASDAQ: TSLA) have received a price target of $590. These are the details.
|
https://pulse2.com/tsla-stock-price-590-target-by-wells-fargo/
|
|
NVDA
| 2021-05-29T10:00:22 |
Why I'm Looking Forward to ZM's Earnings on Tuesday
|
investorplace.com
|
Is ZM stock a good buy ahead of its earnings results next week? Let's take a deeper dive to see why I am looking forward to the release.
|
https://investorplace.com/2021/05/why-im-looking-forward-to-zms-earnings-on-tuesday/
|
|
AMZN
| 2021-05-29T11:21:33 |
With $8.45 billion deal to buy MGM, Amazon scripts its own Hollywood plot twist
|
geekwire.com
|
Amazon's agreement to acquire MGM for $8.
|
https://www.geekwire.com/2021/8-45-billion-deal-buy-mgm-amazon-scripts-hollywood-plot-twist/
|
|
GOOGL
| 2021-05-29T11:58:02 |
Google Cloud Adds Support For Polygon Blockchain Network Data
|
benzinga.com
|
Google BigQuery — a cloud offering meant to enable big data analysis by Alphabet Inc (NASDAQ:GOOGL) (NASDAQ:GOOG) — now added support for data from the Polygon (CRYPTO: MATIC) Ethereum-linked blockchain. What Happened: According to an announcement shared with Benzinga, Google Cloud users will now be able to use the BigQuery service to analyze Polygon on-chain data.
|
https://www.benzinga.com/markets/cryptocurrency/21/05/21341511/google-cloud-adds-support-for-polygon-blockchain-network-data
|
|
META
| 2021-05-28T13:53:47 |
Will inflation hurt Facebook? #AskHalftime
|
youtube.com
|
The "Halftime Report" traders answer viewer questions in #AskHalftime.
|
https://www.youtube.com/watch?v=t1vz_khXc0k
|
|
AAPL
| 2021-05-28T13:54:00 |
Epic vs. Apple: The (predicted) verdict is in
|
marketwatch.com
|
Though few expect the judge to force major changes at the App Store or deem Apple a monopolist, they fully expect prescriptive measures that could address 30% commission fees for large developers as well as accommodations to Apple's payment system.
|
https://www.marketwatch.com/story/epic-vs-apple-the-predicted-verdict-is-in-11622224463
|
|
AAPL
| 2021-05-28T13:55:00 |
How profitable is Apple's App Store? Even a landmark antitrust trial couldn't tell us
|
marketwatch.com
|
During the trial of Epic Games Inc.'s antitrust lawsuit against Apple Inc., investors got a glimpse of how profitable the App Store may possibly be, even though Apple disputed that evidence.
|
https://www.marketwatch.com/story/how-profitable-is-apples-app-store-even-a-landmark-antitrust-trial-couldnt-tell-us-11622224506
|
|
COST
| 2021-05-28T14:03:03 |
Why BofA Is Bullish On Costco Stock After Q3 Earnings
|
benzinga.com
|
Costco Wholesale Corporation (NASDAQ: COST) reported fiscal third-quarter results that were ahead of expectations, driven by higher comps and lower COVID-19 costs, according to BofA Securities. The Costco Wholesale Analyst: Robert Ohmes maintained a Buy rating for Costco Wholesale and raised the price target from $415 to $435.
|
https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21341272/why-bofa-is-bullish-on-costco-stock-after-q3-earnings
|
|
AMGN
| 2021-05-28T14:08:29 |
Amgen gets FDA approval for new lung-cancer drug
|
marketwatch.com
|
Shares of Amgen were up 0.5% in trading on Friday after the Food and Drug Administration said it approved Amgen's Lumakras, a new therapy for adults with a certain type of non-small cell lung cancer. Before patients qualify for treatment, they have to test positive for the KRAS G12C mutation and have previously undergone treatment.
|
https://www.marketwatch.com/story/amgen-gets-fda-approval-for-new-lung-cancer-drug-2021-05-28
|
|
QCOM
| 2021-05-28T14:14:01 |
This Little-Known 5G Company Has Dual Identities – And Huge Upside Potential
|
investorplace.com
|
5G will be the norm before we know it, which means we're going to need networks that are both quick and secure. This company fits the bill.
|
https://investorplace.com/2021/05/this-little-known-5g-company-has-dual-identities-and-huge-upside-potential/
|
|
AMZN
| 2021-05-28T14:18:56 |
New Bill To Impose Counterfeit Goods Sale Liability On Amazon, eBay: Bloomberg
|
benzinga.com
|
A new U.S. bill will impose higher liability from Amazon.com Inc (NASDAQ: AMZN) and eBay Inc's (NASDAQ: EBAY) e-commerce platforms for the hazardous counterfeit sale of health risk products like exploding Apple Inc (NASDAQ: AAPL) iPhone chargers or defective personal protective equipment by third-party vendors, Bloomberg reports. The platforms will have to validate manufacturer identity and permanently ban serial offenders from gaining liability immunity.
|
https://www.benzinga.com/news/21/05/21343645/new-bill-to-impose-counterfeit-goods-sale-liability-on-amazon-ebay-bloomberg
|
|
AMGN
| 2021-05-28T14:29:14 |
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
|
benzinga.com
|
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation. The approval covers the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy.
|
https://www.benzinga.com/general/biotech/21/05/21343829/amgens-first-kras-targeted-therapy-lumakras-scores-fda-approval-for-lung-cancer
|
|
AAPL
| 2021-05-28T14:49:59 |
Why New Street Research downgraded Apple to sell
|
youtube.com
|
CNBC's Kelly Evans discusses the outlook for Apple and why investors may want to consider selling its stock with Pierre Ferragu, New Street Research managing partner. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis.
|
https://www.youtube.com/watch?v=WBuo8zwqRfU
|
|
AAPL
| 2021-05-28T14:51:50 |
Apple investors don't seem to care after stock receives an uncommon ‘sell' rating
|
invezz.com
|
Apple Inc. (NASDAQ: AAPL) received a rare ‘sell' rating from the New Street Research analyst Pierre Ferragu, according to a story in The Street. The analyst has a price target of $90 on the stock, which implies a potential downside of 28% from $125, the price at which the stock is currently trading.
|
https://invezz.com/news/2021/05/28/apple-investors-dont-seem-to-care-after-stock-receives-an-uncommon-sell-rating/
|
|
TSLA
| 2021-05-28T15:47:14 |
Tesla starts using cabin cameras to make sure drivers are paying attention
|
cnbc.com
|
The technical changes come amid regulatory scrutiny of Tesla vehicle safety in the U.S. and abroad.
|
https://www.cnbc.com/2021/05/28/tesla-starts-using-cabin-cameras-for-driver-monitoring.html
|
|
AMGN
| 2021-05-28T16:00:00 |
This Just-Approved Amgen Drug Is the First to Hit a Hard Target in Cancer
|
barrons.com
|
Amgen's newest cancer drug is the first KRAS inhibitor class to gain approval, after decades of trying by other drug developers. Mirati hopes to follow fast.
|
https://www.barrons.com/articles/amgen-stock-cancer-drug-kras-51622231939
|
|
NVDA
| 2021-05-28T16:00:55 |
Strong Week For Stock Market Rally; Nvidia, Goldman Near Buy Points, New IPO UiPath Backtracks
|
youtube.com
|
Strong week for stock market rally; Nvidia, Goldman near buy points, new IPO UiPath backtracks. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.
|
https://www.youtube.com/watch?v=1M23RP7Nm6I
|
|
ADBE
| 2021-05-28T16:05:00 |
Adobe Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
|
businesswire.com
|
SAN JOSE, Calif.--(BUSINESS WIRE)--Adobe (Nasdaq:ADBE) today announced that it recently became aware of an unsolicited "mini-tender" offer by Tutanota LLC (“Tutanota”) to purchase up to one million shares of Adobe's common stock, representing significantly less than one percent of Adobe's common stock outstanding. The offer price of $565 per share is conditioned on, among other things, the closing price per share of Adobe's common stock exceeding $565 per share on the last trading day before the offer expires. This means that unless Tutanota waives this condition, Adobe stockholders who tender their shares in the offer will receive a below-market price. Adobe cautions stockholders that Tutanota can extend the offer for successive periods of 45 to 180 days, in which case payment would be delayed beyond the scheduled expiration date of Friday, June 4, 2021. There is no guarantee the conditions of the offer will be satisfied. Adobe recommends that stockholders do not tender their shares in response to Tutanota's offer because the offer is at a price below a conditional market price for Adobe's common stock and subject to numerous additional conditions. Stockholders who have already tendered their shares may withdraw them at any time prior to 5:00 p.m., Eastern Time, on Friday, June 4, 2021, in accordance with the offering documents. Adobe does not endorse Tutanota's unsolicited mini-tender offer and is not associated in any way with Tutanota, its mini-tender offer, or its mini-tender offer documents. Tutanota's mini-tender offer seeks less than five percent of Adobe's outstanding common stock. Mini-tender offers seek to acquire less than five percent of a company's outstanding shares, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (“SEC“) that apply to offers for more than five percent of a company's outstanding shares. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws. Tutanota has made similar unsolicited mini-tender offers for stock of other public companies. The SEC has cautioned investors about these offers, noting that “some bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC's guidance to investors on mini-tenders is available at https://www.sec.gov/reportspubs/investor-publications/investorpubsminitendhtm.html. Adobe encourages brokers and dealers, as well as other market participants, to review the SEC's letter regarding broker-dealer mini-tender offer dissemination and disclosure at https://www.sec.gov/divisions/marketreg/minitenders/sia072401.htm. Stockholders should obtain current market quotations for their shares, consult with their broker or financial advisor, and exercise caution with respect to Tutanota's mini-tender offer. Adobe requests that a copy of this news release be included with all distributions of materials related to Tutanota's mini-tender offer related to Adobe's common stock. About Adobe Adobe is changing the world through digital experiences. For more information, visit www.adobe.com. © 2021 Adobe. All rights reserved. Adobe and the Adobe logo are either registered trademarks or trademarks of Adobe in the United States and/or other countries. All other trademarks are the property of their respective owners.
|
https://www.businesswire.com/news/home/20210528005461/en/Adobe-Recommends-Stockholders-Reject-%E2%80%9CMini-Tender%E2%80%9D-Offer-by-Tutanota-LLC
|
|
ADBE
| 2021-05-28T16:05:00 |
Adobe Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
|
businesswire.com
|
SAN JOSE, Calif.--(BUSINESS WIRE)--Adobe (Nasdaq:ADBE) today announced that it recently became aware of an unsolicited "mini-tender" offer by Tutanota LLC (“Tutanota”) to purchase up to one million shares of Adobe's common stock, representing significantly less than one percent of Adobe's common stock outstanding. The offer price of $565 per share is conditioned on, among other things, the closing price per share of Adobe's common stock exceeding $565 per share on the last trading day before th
|
https://www.businesswire.com/news/home/20210528005461/en/Adobe-Recommends-Stockholders-Reject-%E2%80%9CMini-Tender%E2%80%9D-Offer-by-Tutanota-LLC/
|
|
COST
| 2021-05-28T16:13:37 |
Your next Costco run could be more expensive as the company warns of expected price hikes for key goods, including trash bags, cheese, plastic plates, and beef (COST)
|
businessinsider.com
|
Costco Chief Financial Officer Richard Galanti called out rising inflation in the big box company's Thursday earnings call, noting that selling prices for staples like paper goods, meat, cheese, and trash bags are up. Galanti rattled through a number of "inflationary soundbites" with analysts on the call and shared a number of products experiencing spiking prices, as well as the reasons for rising costs.
|
https://www.businessinsider.com/costco-rising-prices-consumer-goods-beef-cheese-plastics-2021-5
|
|
NVDA
| 2021-05-28T16:24:41 |
Inside the Mind of James Anderson, Part 2
|
gurufocus.com
|
I would like to start with a quick story. I used to work in trading.
|
https://www.gurufocus.com/news/1441305/inside-the-mind-of-james-anderson-part-2
|
|
META
| 2021-05-28T16:39:57 |
BD8's Barbara Doran on what she's been buying
|
youtube.com
|
Barbara Doran, BD8 Capital Partners CEO, joins ‘Closing Bell' to discuss the stocks that she has been buying, such as Facebook, Visa and Mastercard.
|
https://www.youtube.com/watch?v=nhUezB7RoTs
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.